- An ultra-premium cannabis grower for the medicinal and recreational cannabis markets in California, Sonoma Biologics Corp. is committed to using only organic-equivalent outdoor growing techniques to cultivate its cannabis product at a fraction of the cost of its competitors
- Sonoma Biologics’ target locations cover three well-known wine country counties, offering considerable branding opportunities
- The global market for legal cannabis is expected to reach $84 billion by 2028, growing at a CAGR of 14.3% from 2021 to 2028
- The California market for cannabis is expected to reach $6 billion by 2025 and account for roughly a sixth of all legal cannabis sales in the United States
- Sonoma Biologics’ seasoned management team is highly skilled at handling large commercial farming operations
Sonoma Biologics is an ultra-premium cannabis grower focused on the medicinal and recreational cannabis markets. The company’s business model includes acquiring additional farming/cultivation properties in the prestigious wine counties of California, as well as continuing to enter into joint ventures and revenue sharing cultivation opportunities with other landowners/farmers/vineyards. The company’s goal is to become one of the largest organic-equivalent, environmentally friendly cannabis suppliers in northern California.
Sonoma Biologics’ use of solar power in its low cost, highly efficient growth processes exemplifies the company’s commitment to having as close to zero environmental impact as possible.
The company currently holds local and state cannabis cultivation licenses for its existing facilities. Since entering the cannabis industry, Sonoma Biologics products have passed stringent California quality control laboratory testing each year. The company exclusively adheres to organic cultivation methods, reinforcing its commitment to yielding the highest quality cannabis.
Sonoma Biologics is currently prepping to certify with the State of California’s comparable-to-organic cannabis standards. The OCal Program will ensure that cannabis products bearing the OCal seal have been certified to consistent, uniform standards comparable to the National Organic Program.
Sonoma Biologics has been cultivating premium cannabis outdoors for the last four years, taking advantage of the favorable climate in its operating region. The company is currently aggressively expanding its model. As the California weather minimizes the need for climate control technology and artificial lighting, the company boasts a significantly lower cost of production when compared to both indoor and outdoor grow operations in areas with less suitable climates. The company pours its efforts into screening and optimizing specific genetic strains that grow the best in local farming conditions, thereby maximizing its yields and taking full advantage of the well-known benefits of the Sonoma soils.
Sonoma Biologics’ target locations span three well-known wine country counties in California: Sonoma County, Mendocino County and Lake County.
The company’s current locations in Sonoma County provide for up to two acres of outdoor cultivation (pending licensing and county regulations).
The company has a Mendocino joint venture (“JV”) agreement, which, when completed, will expand its overall cannabis related assets and operations. The joint venture provides the company with additional licensed cultivation, licensed nursery operation, potential dispensary (pending licensing) and employees.
Highlights of the company’s manufacturing capabilities with the JV include:
- An existing 5,000 square foot warehouse currently being built out to facilitate manufacturing and distribution and
- Additional proposed facilities to manufacture cannabis-related products.
With applications for manufacturing currently in process, these facilities offer further scalability opportunities for the company. Additionally, the Anderson Valley location can intake surplus cannabis from numerous licensed farms in the region and focus on “onsite” and “managed” streams for superior economics.
Investing in California Cannabis
Sonoma Biologics is currently accepting investments from accredited investors under Rule 506(c) of Regulation D. The minimum investment amount is $5,000 per investor, with the overall goal of raising $10 million. The company is also preparing a Reg A+ filing with the SEC for summer 2021. In alignment with its environmentally low impact business strategy, the company has created a streamlined, completely paperless online subscription process for investors.
The company offers those looking to invest in California-grown cannabis the opportunity to invest at an attractive valuation. Sonoma Biologics’ operations are large-scale, low-cost and managed by industry leaders with experience in large-scale farming, making the company an attractive investment opportunity in the expanding cannabis market in California and worldwide.
The global legal cannabis market is estimated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028 (https://ibn.fm/xSpyM). Of the $24.6 billion in global cannabis industry revenue reported in 2020, 60.3% was attributed to the recreational adult-use segment. Furthermore, 91.1% of the revenue can be attributed to North America, spurred by early legalization of medical and recreational cannabis in a number of jurisdictions (https://ibn.fm/3Nn42).
The California market for cannabis is expected to reach $6 billion by 2025 and account for roughly a sixth of all legal cannabis sales in the United States (https://ibn.fm/ugi3q).
Paul Caracciolo is the Chief Executive Officer and Co-Founder of Sonoma Biologics Corp. He has a Master’s in Biochemistry from the University of Colorado. After obtaining his degree, he developed human-grade biopharmaceuticals for a company that was eventually acquired by Amgen. Mr. Caracciolo has spent much of his career in the health care industry, holding positions such as Chief Technology Officer for Dignity Health, Duke University Health System and Stanford’s Hospitals and Clinics. In 2008, Mr. Caracciolo and his wife, Margaret, founded Mill Station Vineyards. Mill Station spans 8.5 acres of ultra-premium Pinot Noir grapes, sold and used in some of the most coveted Pinot Noir blends in the Russian River Valley.
Hal Reuling is the owner of the Anderson Valley Property. He has a long history of real estate development and management projects, from inception to realization. He began his career as a general contractor in Colorado, establishing Bluefootprint Construction and specializing in single-family and custom-built homes. Mr. Reuling’s next venture took him to Florida, where he developed raw land parcels into subdivisions. In 2007, he moved to Northern California to capitalize on property development, including that of the cannabis industry. Durango Organics approached Mr. Reuling in 2015 to design and build a 20,000 square foot fully integrated cultivation facility. More recently, he developed a 110-acre, 11-lot cultivation site in Southern Colorado. He purchased the Anderson Valley Property in 2016 as California began passing cannabis laws. Now, it is being used for co-developing into cultivation, nursery and manufacturing.
Alexander Somjen, Director, has extensive experience serving as an officer and director of publicly listed and privately held companies. Since December 2019, he has served as President of Hollister Cannabis Inc., a diversified, multi-state cannabis company whose securities are quoted on the Canadian Securities Exchange (“CSE”) and the OTC Pink Market maintained by OTC Markets. Hollister provides manufacturing and white label services to help build new brands and support influencers and is also involved with the manufacturing of various cannabis related products (such as pre rolls, capsules and vape formulation). Additionally, since January 2018, he served as President and CEO of Global Care Capital Inc. (formerly Rescinco Capital Partners Inc.), whose securities are quoted on the CSE and the OTC Pink Market. Global Care Capital is a global investment company which specializes in providing early-stage financing to private and public companies. Global Care Capital also has a sector focus on cannabis pharmaceutical opportunities. Mr. Somjen was Vice President of Capital Structure Products at Desjardins Capital Markets from January 2015 to January 2018, where he served as the co-head of the Capital Structure Products desk and advised issuers (namely banks) on subordinated debt and hybrid and preferred share markets. He held other roles with Desjardins Capital Markets from January 2008 to January 2015, including serving as an associate in the fixed income group (January 2012 to January 2015) and as a trader in the fixed income group (January 2008 to January 2012). Mr. Somjen received a bachelor’s degree in economics from the University of Toronto and is working to obtain an Executive MBA from the Instituto de Empresa Business School (“IE”) in Madrid, Spain.
Robert Metcalfe, Director, has been a partner at the law firm of Metcalfe, Blainey & Burns LLP since 2001. Prior to that he was a senior partner with the law firm of Lang Michener LLP for 20 years. He is the former President and Chief Executive Officer of Armadale Properties and counsel to all the Armadale Group of Companies, which boasts significant holdings across numerous industries including finance, construction of office buildings, airport ownership and management, land development and automotive dealerships, as well as newspaper publishing, radio and television stations. Mr. Metcalfe was a director of Canada Lands Company Ltd., one of the largest real estate corporations in Canada, and was a director and Chairman of the Board of CN Tower Ltd., the tallest communications structure in the world. Throughout his career, Mr. Metcalfe has served as a director of numerous public and private corporations and currently serves as director of publicly listed companies Gran Colombia Gold Corp., (Director and Chairman of the Corporate Governance and Nominating Committee, as well as a member of the Audit Committee); Xinergy Corp. (Lead Director and Chairman of the Audit Committee); Alberta Oil Sands (Director and Chairman of the Board); Agility Health Inc. (Chairman of the Compensation Committee and member of the Audit Committee); and Ivernia Inc. (Member of the Audit Committee, Member of the Corporate Governance Committee and Chairman of the Compensation Committee). As a director and shareholder, Mr. Metcalfe has been engaged in numerous acquisitions, divestitures, corporate financing and corporate improvements, as well as serving on special committees across many sectors. He is a member of the Institute of Corporate Directors and a member in good standing of the Law Society of Upper Canada.
For more information, visit the company’s website at www.OwnSonomaBiologics.com.
NOTE TO INVESTORS: The latest news and updates relating to Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma